Company RetinalGenix Technologies Inc.

Equities

RTGN

US76133Y1055

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sector Other Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:47:02 2024-02-22 EST			5-day change	1st Jan Change
3.5 ^USD	+12.90%		-.--%	+13.27%

04-01	RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
02-09	RetinalGenix Technologies Inc. announced that it has received $4.65 million in funding	CI

RetinalGenix Technologies Inc. is an ophthalmic research and development company. The Company is focused on creating solutions to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders and to enable the early detection and treatment of multiple systemic diseases through a combination of therapeutic medications and medical device technologies. The Company is focused on preventing vision loss and blindness due to ocular diseases, including diabetic retinopathy and maculopathy, in its first two devices: Retinal Imaging Screening Device and RetinalCam. Retinal Imaging Screening Device is a portable, retinal imaging system providing a wide field of view without requiring pupil dilation. RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real time communication and alerting system for physicians available 24/7. The Company is also engaged in the development of its product candidates: RTG-2023 and RTG-2024.

Managers	Title	Age	Since
Erhan Gunday FOU	Founder	-	-
Jerry Katzman CEO	Chief Executive Officer	71	18-07-31
Virender Ahluwalia DFI	Director of Finance/CFO	66	11-29
Alex Hsia CTO	Chief Tech/Sci/R&D Officer	-	-

Members of the board	Title	Age	Since
Jerry Katzman CEO	Chief Executive Officer	71	18-07-31
Herbert Gould BRD	Director/Board Member	95	19-03-31
Vinay Mehindru BRD	Director/Board Member	-	22-07-25
Dessislava Boneva BRD	Director/Board Member	53	12-03

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	17,785,478	5,334,114 ( 29.99 %)	0	29.99 %

Name	Equities	%	Valuation
Jerry Katzman 40.48 %	7,200,164	40.48 %	24 M $
Steven Bayern 28.49 %	5,067,000	28.49 %	17 M $
Herbert Gould 2.586 %	460,000	2.586 %	2 M $
Dessislava Boneva 0.1406 %	25,000	0.1406 %	84 375 $
Vinay Mehindru 0.000000 %	0	0.000000 %	- $
Virender Ahluwalia 0.000000 %	0	0.000000 %	- $

RetinalGenix Technologies, Inc.

1450 North McDowell Bouleverd Suite 150

94954, Petaluma

http://www.retinalgenix.com

address RetinalGenix Technologies Inc.(RTGN)

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
RETINALGENIX TECHNOLOGIES INC.	+13.27%	62.25M
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research